Lupus

Voclosporin, when added to mycophenolate mofetil and low-dose steroids, results in higher complete renal response rates in patients with lupus nephritis, compared with mycophenolate mofetil and low-dose steroids alone, according to data.

Although the seroprevalence of SARS-CoV-2 in patients with immune-mediated inflammatory diseases is comparable to the general population, increased systemic inflammation among these patients is linked to symptomatic COVID-19, according to researchers.

Studies that feature work participation as an outcome in patients with inflammatory arthritis should identify key contextual factors — such as job type or social security system — upfront, according to new “points to consider” from EULAR.

The FDA has issued a warning letter to an online pharmacy for allegedly selling unapproved and misbranded drugs, including hydroxychloroquine and chloroquine, for the treatment of COVID-19, lupus, rheumatoid arthritis and other diseases.

There is no association between a child’s ethnicity and the risk for neonatal lupus erythematosus, nor for any specific disease symptoms, according to data published in The Journal of Rheumatology.

After decades of research advances and reverses, blocking the interferon receptor in lupus may finally be showing consistent clinical benefit, according to a presentation at the United Rheumatology Spring Virtual conference.

Given the link between puberty and autoimmune rheumatic disease, a group of researchers has recommended that clinical assessments of young patients with such conditions record pubertal issues at every encounter.

Darker skin tones are “significantly underrepresented” in rheumatology clinical image banks, including the American College of Rheumatology Image Library and The New England Journal of Medicine Images in Clinical Medicine, according to data.

The incidence of scleritis declined by about a third in the United Kingdom between 1997 and 2018, according to data published in Arthritis & Rheumatology.

Although cost, side effects and a busy schedule are among the most cited barriers to lupus treatment adherence in racial minorities, specific hurdles vary by patient and adherence level, requiring a personalized approach, according to data.